| 书目名称 | Lung Cancer: | | 副标题 | Prevention, Manageme | | 编辑 | David J. Stewart | | 视频video | | | 概述 | Provides full coverage of established and emerging therapies, including novel targeted and antiangiogenic agents.Evaluates the mechanisms of drug resistance and the therapeutic potential of new target | | 丛书名称 | Current Clinical Oncology | | 图书封面 |  | | 描述 | Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as d | | 出版日期 | Book 2010 | | 关键词 | Antiangiogenesis; Cancer; Carcinom; Clinical trials; Lung; Malignancy; Mesothelioma; Non-small cell lung ca | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-60761-524-8 | | isbn_softcover | 978-1-61779-684-5 | | isbn_ebook | 978-1-60761-524-8Series ISSN 2364-1134 Series E-ISSN 2364-1142 | | issn_series | 2364-1134 | | copyright | Humana Press 2010 |
The information of publication is updating
|
|
发表于 2025-3-21 19:41:46
